Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas (EPL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00779337
Recruitment Status : Completed
First Posted : October 24, 2008
Last Update Posted : May 22, 2012
The Atlantic Philanthropies
Australian Department of Industry, Tourism and Resources
British Society for Haematology
National Health and Medical Research Council, Australia
Information provided by (Responsible Party):
Maher Gandhi, Queensland Institute of Medical Research

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : January 2012
  Actual Study Completion Date : May 2012